Company intelligence / Profile preview
Clavis Pharma
Oslo, Norwayclavispharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Developed novel anti-cancer drugs using Lipid Vector Technology to improve efficacy and reduce side effects of established drugs. Lead product elacytarabine showed promising survival data in late-stage acute myeloid leukemia.
- Therapeutic areas
- OncologyImmunologyInfectious Diseases
- Modalities
- Small moleculesLipid-conjugated drugs
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Clovis Oncology ($380 million partnership in 2009, expanded to $205 million global rights deal in 2010)Translational Therapeutics, Inc.Mount Sinai School of Medicine
Beyond the preview
Go deeper on Clavis Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Clavis Pharma.